HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

tropisetron (Navoban)

Subscribe to New Research on tropisetron

Also Known As:

Navoban; (3 alpha-tropanyl)-1H-indole-3-carboxylic acid ester; ICS 205-930; ICS-205-930; ICS-205930; Novartis brand of tropisetron hydrochloride; indole-3-carboxylic acid tropine ester; tropisetron hydrochloride; 1H-Indole-3-carboxylic acid, 8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, endo-

Networked: 373 relevant articles (102 outcomes, 112 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 60
- 2-Ring Heterocyclic Compounds
  - Indoles: 95
    - tropisetron: 373

Experts

1.	Müller, W: 22 articles (10/2006 - 01/2000)
2.	Stratz, T: 18 articles (10/2006 - 01/2000)
3.	Färber, L: 10 articles (01/2004 - 01/2000)
4.	Späth, M: 9 articles (01/2004 - 01/2000)
5.	Hashimoto, Kenji: 8 articles (01/2015 - 07/2005)
6.	Dehpour, Ahmad Reza: 7 articles (12/2015 - 05/2011)
7.	Haus, U: 7 articles (01/2004 - 01/2000)
8.	Fujii, Yoshitaka: 6 articles (12/2011 - 01/2005)
9.	Rahimian, Reza: 4 articles (12/2015 - 05/2011)
10.	Fakhfouri, Gohar: 4 articles (12/2015 - 05/2011)

Related Diseases

1.	Vomiting 01/01/1994 - "Tropisetron at doses of at least 0.20 mg/kg was significantly more effective in preventing vomiting than lower tropisetron doses or placebo, both in terms of treatment failure (> four vomits) (P = 0.015) and patient and investigator efficacy ratings (P = 0.04 for investigator rating; P = 0.035 for patient rating). " 08/01/1995 - "3) The anti-emetic effects of tropisetron on acute and delayed emesis and vomiting were rated as "markedly effective" in 6 out of 11 patients (54.6%) and "effective" in 1 out of 11 patients (9.1%) on day 1; vomiting did not occur in any of these 7 patients. " 10/01/1994 - "Improved control of emesis also was observed over 4 consecutive days of follow-up in the tropisetron group. " 02/01/1995 - "The role of Navoban for delayed emesis must be evaluated in future trials. " 11/01/1994 - "In this study failures ( > 3 vomiting) were rescued with a second infusion of tropisetron (5-mg fixed dose). "
2.	Nausea 10/01/2011 - "By 60 min and thereafter, the decrease in nausea score from baseline was greater (although not significantly so) in the tropisetron group. " 02/01/2006 - "However, tropisetron reduced post-operative nausea." 02/01/2006 - "In the post-operative questionnaire, the patients reported less post-operative nausea in the tropisetron group than in the placebo group (P < 0.01). " 09/01/1998 - "On Day 3, complete protection from nausea was achieved in 65% of patients receiving tropisetron and in 51% of patients receiving placebo (P = 0.0304). " 10/01/1994 - "Total control of nausea was achieved in 84% and 80% of patients receiving tropisetron at these dosages. "
3.	Postoperative Nausea and Vomiting (PONV) 10/01/1998 - "We conclude that single-dose tropisetron 5 mg is more effective than tropisetron 2 mg in the prevention of PONV after breast surgery. " 10/01/1998 - "In this randomized, double-blind, placebo-controlled study, we compared the efficacy of tropisetron 5 mg with tropisetron 2 mg for the prevention of postoperative nausea and vomiting (PONV) after breast surgery. " 01/01/1996 - "In a prospective, randomized, multicentre, double-blind, placebo-controlled study, we have compared the efficacy of a single i.v. dose of tropisetron 0.5 mg, 2 mg and 5 mg in the prevention of postoperative nausea and vomiting (PONV). " 12/01/2006 - "The incidence of postoperative vomiting (POV) was statistically more significant in the placebo group at 2, 6 and 24 hours, when compared to the study groups (p< 0.001), but there was no significant difference among tropisetron groups at 6-24 hours (p>0.05). " 04/01/2006 - "The aim of the study was to compare the effects of early vs late intraoperative administration of tropisetron with regard to prevention of PONV during the first 48 h after extubation. "
4.	Neoplasms (Cancer) 01/01/2006 - "The study sample consisted of 288 cancer patients randomly allocated (3:4 ratio) into two treatment groups: 120 patients received prophylactic antiemetic treatment with tropisetron and 168 patients received rescue tropisetron. " 09/01/2008 - "The acute effect of tropisetron on ECG parameters in cancer patients." 04/01/2000 - "Tropisetron is a new 5HT3 receptor antagonist and is successfully used in paediatric patients receiving cancer therapy. " 09/01/1995 - "Tropisetron was given to 15 children (8 boys and 7 girls, ranging from 6 months to 17 years of age) with miscellaneous neoplasms. " 08/01/1994 - "Tropisetron was given to 15 children (eight boys and seven girls 18 months to 18 years of age) with miscellaneous neoplasms. "
5.	Pain (Aches) 01/01/2004 - "A significant reduction of the pain intensity was achieved by using tropisetron 5 mg per day. " 01/01/2000 - "A more favourable and persistent effect on pain, combined with a simultaneous significant improvement in various vegetative and functional symptoms was achieved with five days treatment with 2 mg tropisetron i.v. per day. " 01/01/2003 - "An open study of selected cases revealed that 2 mg of tropisetron daily for 5 days also yielded satisfactory pain reduction, whereas this was not observed in a placebo-controlled double-blind study. " 01/01/2002 - "There were no significant differences between the tropisetron and the corticosteroid/anesthetic group in terms of pain at rest or on movement during the study. " 01/01/2004 - "Treatment with tropisetron leads in a subgroup of FM patients to pain reduction. "

Related Drugs and Biologics

1.	Dexamethasone (Maxidex)
2.	Ondansetron (Zofran)
3.	Cisplatin (Platino)
4.	tropisetron (Navoban)
5.	Granisetron (Kytril)
6.	5-HT3 Serotonin Receptors (5 HT3 Receptor)
7.	Serotonin (5 Hydroxytryptamine)
8.	Metoclopramide (Reglan)
9.	dolasetron mesylate (dolasetron)
10.	Droperidol

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Tonsillectomy
3.	Laparoscopic Cholecystectomy
4.	Injections
5.	Bone Marrow Transplantation (Transplantation, Bone Marrow)